Wilbur H. Chen MD , MS, FACP, FIDSA

International Health, Travel & Tropical

Professor of Medicine, University of Maryland School of Medicine

Center for Vaccine Development685 W. Baltimore Street, suite 480Baltimore, MD 21201
Phone+1 410-706-5328
Fax+1 410-706-6205

Dr. Chen is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile Already have an account?

Summary

Dr. Wilbur Chen is the Frank M. Calia, MD Endowed Professor of Medicine, an infectious disease physician-scientist at the University of Maryland School of Medicine, affiliated with the University of Maryland Medical Center. He received his medical degree from Howard University College of Medicine and has been in practice 18 years. He specializes in international health, travel & tropical and is the Director of the University of Maryland, Baltimore Travel Medicine Practice. He conducts vaccine research on diarrheal diseases, influenza, and tropical medicine.

Education & Training

University of Maryland School of MedicineMS, Clinical Research, 2004 - 2008
University of Maryland School of MedicinePost-Doctoral Fellowship, 2004 - 2006
University of MarylandFellowship, Infectious Disease, 2002 - 2004
Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Howard University College of MedicineClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MD State Medical License 2004 - 2028

Clinical Trials

H5N1 (Clade 2) Vaccination of Adults and Elderly
COMPLETED
PHASE1, PHASE2
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
COMPLETED
PHASE1
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
COMPLETED
PHASE2

Publications & Presentations

PubMed

Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial.
Deborah R Leitner, Stephen R Walsh, Masataka Suzuki, Michaël Desjardins, Alisse Hannaford
The Lancet. Infectious Diseases. 2026-05-01
1 citations
humoral immunity during the first 2 years of life in children from endemic areas.
Esther Ndungo, Ushasi Bhaumik, Yuanyuan Liang, Wilbur H Chen, Mark A Travassos
Mbio. 2025-05-14
Mortality Trends in Pre-COVID-19 and COVID-19 Eras Among Oldest Veterans.
Jessica Palmer, Maithri Kondapaka, Brock A Beamer, Tariq Siddiqui, John D Sorkin
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2025-05-05

Journal Articles

Responses of the Human Gut Escherichia Coli Population to Pathogen and Antibiotic Disturbances
Wilbur Chen, MD, mBio

Press Mentions

NFID Announces Recipients of Prestigious 2026 Infectious Disease AwardsMay 18th, 2026
A Common Stomach Bug Has Become Harder to TreatApril 24th, 2026
A New CDC Recommendation Could Mean a Big Change for Childhood VaccinesDecember 6th, 2025

Grant Support

Advanced Development of a Combined Shigella-ETEC VaccineUNIVERSITY OF MARYLAND BALTIMORE2023–2028
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.UNIVERSITY OF MARYLAND BALTIMORE2020–2025
Bacteriophage-based approach for managing Shigella infectionsINTRALYTIX, INC.2020–2025
Clinical Trial: Phase I/II Study Of A Booster Dose Of A/H5n1/Indonesia/05/05 (ClNational Center For Research Resources2009